At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 16 enrolled
Drug / intervention
20% subcutaneous immunoglobulindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non Hodgkin's Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab
In Brief
A Phase 3 clinical trial evaluating 20% subcutaneous immunoglobulin for Secondary Immune Deficiency. Completed, enrolled 16 participants across 1 site.
Detailed Summary
To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal immune system putting them at increased risk of infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSecondary Immune Deficiency
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartJul 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedJul 7, 2017
Enrollment StartJul 21, 2017
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.0 years ago
Interventions
20% subcutaneous immunoglobulindrug
Subcutaneous Immunoglobulin